StemCells Inc. (Nasdaq: STEM) is a clinical-stage biotechnology company focused on the development and commercialization of cell-based therapeutics to treat diseases of the central nervous system and liver. Though controversial to many people, cell-based discoveries are important in medical and scientific advances.

The company’s HuCNS-SC product candidate (purified human neutral stem cells) is undergoing clinical trials to treat retinal and spinal cord damage and will soon be showcased to neuroscientists around the globe. StemCells today announced it will present the results of its retinal degeneration and spinal cord injury research program at the Society for Neuroscience Annual Meeting later this month in Washington, D.C.

As the world’s largest organization centered on advances in understanding the brain and nervous system, The Society for Neuroscience has established this annual meeting to allow neuroscientists all around the world to present, observe and discuss scientific breakthroughs, technology and advances. StemCells has established an ongoing

We often take our eyesight for granted until it’s too late. More than 1.7 million people over the age of 65 are afflicted with age-related macular degeneration, taking away the precious gift of sight. The loss of function in retinal cells can lead to impairment or total loss of vision. While scientific advances to treat diseases of the eye are constantly being made, approximately 65,000 people in the United States are affected by the most common types of retinitis pigmentosa.

As its name implies, StemCells Inc. (Nasdaq: STEM) concentrates on the discovery, development and commercialization of cell-based therapeutics to treat diseases affecting the central nervous system and liver. The company today announced that its HuCNS-SC product candidate, when transplanted into a well-established animal model, can protect the retina from progressive degeneration, which can lead to the loss of vision in age-related eye diseases.

The study was conducted by Dr.